secwatch.observer — SEC 8-K summary
======================================

Issuer:     Omega Therapeutics, Inc. (—)
CIK:        0001850838
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001193125-24-258595
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omega Therapeutics CEO Mahesh Karande resigns; Kaan Certel appointed CEO and director
--------------------------------------------------------------------------------

- Mahesh Karande resigned as President, CEO, and Board member effective November 14, 2024.
- Kaan Certel, former Chief Business Officer, appointed President, CEO and Class I director same day.
- Certel receives $520,000 base salary, 50% bonus target, and option to purchase 340,000 shares.
- Karande severance includes base salary through May 25, 2025 or new employment, plus $250k transaction bonus.
- Entered subleases with Flagship affiliates for ~22,350 rentable sq ft through August 31, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850838/000119312524258595/0001193125-24-258595-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850838/000119312524258595/d736299d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-258595

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer